Our Take
A large-scale microbiome signature for colorectal cancer exists and correlates with fibre intake, but the study does not yet show that modifying the microbiome alone prevents cancer or reduces risk independent of diet.
Why it matters
This is the largest single-disease microbiome meta-analysis to date, establishing a reproducible pattern across geographies and sequencing methods. For clinicians and researchers, it provides a measurable biomarker; for public health, it reinforces fibre intake as a protective factor.
Do this week
Gastroenterologists: Begin collecting stool microbiome data alongside tissue samples in early-stage colorectal cancer cases to validate the signature's diagnostic utility before relying on it for risk stratification.
A 6,779-sample microbiome meta-analysis confirms a cancer signature tied to diet
Researchers from the European Molecular Biology Laboratory (EMBL) and Leiden University Medical Center re-analysed data from 27 previously published studies, combining 6,779 stool microbiome samples and 906 intestinal tissue samples. The work, published in Cell Host and Microbe, identified a reproducible microbial signature associated with colorectal cancer.
The team documented a significant inverse relationship between dietary fibre intake and colorectal cancer microbiome scores in both cancer patients and people without tumours. Crucially, fibre-based interventions lowered the cancer-associated microbiome score in existing datasets, suggesting the pattern is modifiable.
The signature proved consistent across cohorts, geographies, sequencing methods, and age groups (both early-onset and late-onset colorectal cancer). In tissue samples, cancer-associated microbes were detectable even in early-stage tumours. Stool-based detection accuracy was lower in early-stage cancers and tumours located further upstream in the colon.
Reproducibility across datasets is rare; clinical utility remains unproven
Most microbiome studies fail to replicate outside their original cohort. This analysis succeeded because the researchers standardised re-profiling methods across 34 study populations and applied a machine-learning classifier consistently. That reproducibility is the real finding.
However, the study establishes correlation, not causation. The microbiome signature correlates with low fibre intake and cancer presence, but does not prove that altering the microbiome alone prevents cancer. The protective effect of fibre is well-established epidemiologically; this work shows one potential mechanism (microbial composition) but stops short of demonstrating that reversing the signature reduces cancer incidence independent of continued fibre intake.
The authors note that the approach can be applied to existing microbiome datasets, including dietary intervention trials, to understand how lifestyle factors shape disease-associated patterns. This opens a pathway to prospective validation, but that work has not been done yet.
Audit your microbiome sampling protocol before scaling risk models
If you are developing microbiome-based risk stratification for colorectal cancer, test the signature in your own cohort before deploying it clinically. The study shows the signature is robust across published datasets, but implementation accuracy will depend on your sequencing platform, sample handling, and patient demographics.
For primary care and public health, the takeaway is simpler: the study provides mechanistic support for fibre intake recommendations, but does not introduce a new clinical action. Continue recommending fibre; do not yet order stool microbiome tests for cancer risk assessment outside research settings.